ARTICLE | Company News
Selexis, Progenics deal
July 18, 2016 7:00 AM UTC
Selexis granted Progenics rights to use Selexis’ CHO-M Cell Line and the SUREtechnology platform to develop and manufacture Progenics’ prostate-specific membrane antigen ( PSMA; FOLH1; GCPII) mAb t...